两种自体LAK、IL2疗法对肺癌末梢血T细胞亚群的影响及预后

Study affection on peripheral blood lymphocyte subsets in two kinds of auto LAK/IL2 treatment of primary lung cancer and discuss the prognosis

目的:研究原发性肺癌术后两种自体LAK/IL2疗法对末梢血T细胞亚群的影响,探讨与预后的关系.方法:原发性肺癌术后病人24例,男12例,女12例.术中取肿瘤周围淋巴结及采集末梢血淋巴细胞,分别在IL2存在下培育制备Rn-LAK和Pb-LAK细胞.结合化疗或放疗进行自体LAK/IL2治疗,每2个月～3个月1次,持续2年.LAK治疗前后分别检测末梢血CD3、CD4、CD8和CD4/CD8比值.将其结果分为24例全组、3年以上生存组、2年内死亡组做统计学SPSS10.0配对t检验处理.结果:24例全组中免疫治疗后CD8升高,t＝-4.016,P＝0.001;CD4下降,t＝2.66,P＝0.014;CD4/CD8下降,t＝2.982,P＝0.007.3年以上生存组中CD8上升,t＝-4.032,P＝0.005.2年内死亡组中CD8下降,t＝3.65,P＝0.022.其他指标也有变化,但无统计学显著差异.结论:两种自体LAK/IL2治疗原发性肺癌引起末梢血T细胞亚群的变化,CD8+细胞的升高,提示着良好的预后,是治疗有效的指标.

ve To study affection on peripheral blood T lymphocyte subsets in two kinds of autologous LAK cell trcatmeat of primary lung cancer and discuss the prognosis. Method 24 surgical removed cases of primary lung cancer including 12 cases of male and female respectively. During operation, excising lymph nodes around the tumor and collecting the peripheral blood lymphocytes. With existing of IL-2, Rn-LAK and Pb-IAK cells were cultivating differently. The patients had been received the treatment of IL-2 and autologous LAK cells, once every 2-3 month, for 2 years. To investigate the CD3, CD4, CD8, and the ratio of CD4/CD8 of peripheral blood before and after the treatment of LAK cells respectively. The results of three groups which are the total, the group of alive over 3 years and the death in 2 years were analyzed statistically.Results In total,CD8 increase, t=-4.016, P = 0.001;CD4 decrease, t =2.66, P =0.014;CD4/ CD8 decrease, t = 2.982, P = 0.007. In the group of alive over 3 years, CD8 increase, t = - 4.032, P = 0.005. In the group of death in 2 years, CD decrease, t=3.65, P-0.022. Some other indexes have also changes but without statistic significant difference. Conclusion Two kinds of auto LAK/IL2 cell therapy causes changes in peripheral blood T lymphocyte subsets. The increase of CD8 is an index of efficiency immunotherapy which indicate the good prognosis.